| Literature DB >> 24632543 |
Abstract
PURPOSE OF REVIEW: Understanding the effects of in-utero exposures to environmental agents is of great importance as the resulting deregulation of biological processes can affect both fetal development and health outcomes that manifest later in life. Due to their established role in developmental processes and inherent stability ex vivo, microRNAs (miRNAs) have emerged as attractive candidates to explore the impact of such exposures during this critical window of susceptibility. In this review, we summarize the findings of studies assessing miRNAs as markers of in-utero environmental exposures and as candidates for the molecular basis through which these exposures exert their influence on children's health. RECENTEntities:
Mesh:
Substances:
Year: 2014 PMID: 24632543 PMCID: PMC4176901 DOI: 10.1097/MOP.0000000000000073
Source DB: PubMed Journal: Curr Opin Pediatr ISSN: 1040-8703 Impact factor: 2.856
Studies assessing microRNAs in pediatric health outcomes
| Outcome | miRNA-related assessment | Impact on outcome | Reference |
| Acute lymphocytic leukemia (ALL) | miRNA expression signature profile | Diagnostic: case–control differences | Schotte |
| miRNA expression signature profile | Disease subtype classification: T-ALL/MLL vs. ALL | Schotte | |
| miRNA expression signature profile | Disease subtype classification: T-ALL vs. B-ALL | Fulci | |
| miRNA expression signature profile | Treatment monitoring: response to prednisone | Zhang | |
| miRNA expression signature profile | Clinical prognosis | Zhang | |
| miRNA expression signature profile | Clinical prognosis | Kaddar | |
| Asthma | Presence of SNPs in HLA-G impacts miRNA binding to 3’UTR region | Cause: Case–control difference | Tan |
| Presence of SNPs in miRNA genetic sequence | Cause: Case–control differences | Su | |
| AntagomiR-targeted downregulation of miRNA | Intervention: reduces eosinic inflammation, mucus hypersecretion, TH2 cytokine production, airway hyperresponsiveness | Collison | |
| Autism | miRNA expression signature profile | Diagnostic: Case–control differences | Abu-Elneel |
| miRNA expression signature profile | Diagnostic: Case–control differences | Sarachana | |
| In-silico analysis | Etiology: miRNAs known to be deregulated in autism present in CNV loci | Vaishnavi | |
| Congenital heart disease (CHD) | Presence of SNP in miRNA coding region | Etiology: Case–control differences | Xu |
| In-silico analysis | Etiology: miRNAs present in CHD-related CNV loci | Xing | |
| miRNA expression signature profile | Diagnostic: Case–control differences | Zhu | |
| Cystic fibrosis | miRNA expression signature profile | Diagnostic: Case–control differences | Oglesby |
| In-silico/in-vitro analysis of CFTR 3’UTR binding targets | Etiology: miRNAs regulate CFTR gene expression | Megiorni | |
| In-silico/in-vitro analysis of miRNAs and binding targets involved in CFTR regulation | Treatment: restore function of mutated CFTR protein | Ramachandran | |
| miRNAs involved in CFTR regulation | Cause: miRNAs regulate CFTR gene expression | Oglesby | |
| In-vitro analysis: biogenesis and maturation of candidate miRNA | Cause: RNA binding proteins regulate maturation of miRNA upregulated in CF | Bhattacharyya | |
| Diabetes, Type 1 (T1D) | Candidate miRNA expression analysis | Clinical prognosis | Sebastiani |
| miRNA expression signature profile | Diagnostic: Case–control differences | Nielsen | |
| Candidate miRNA expression analysis | Diagnostic: Case–control differences | Salas-Pérez | |
| Neuroblastoma | miRNA expression signature profile | Disease subtype classification | Chen and Stallings, 2007 [ |
| miRNA expression signature profile | Clinical prognosis | Bray | |
| Obesity | miRNA expression signature profile | Diagnostic: miRNA expression pattern associated with obesity markers | Prats-Puig |
3’ UTR, 3’ untranslated region; ALL, acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CHD, chronic heart disease; CNV, copy number variation; HLA-G, human leukocyte antigen G; miRNA, microRNA; MLL, mixed lineage leukemia; SNP, single nucleotide polymorphism; T-ALL, T-cell acute lymphoblastic leukemia; TH2, Type 2 helper cells.
Impact of in-utero environmental exposures on microRNA expression levels
| Environmental agent | miRNA | Target gene/pathway | Function | Species | Biospecimen/cell type | Reference |
| Xenochemical | ||||||
| BPA | miR-146a | TLR/cytokine signaling | Human | Placenta cell line | Avissar-Whiting | |
| Ethanol | miR-21 | Notch ligand/proliferation of neuroepithelial cells | Mouse | Cerebral cortex-derived neurospheres | Sathyan | |
| miR-335 | Promotes neuronal maturation | |||||
| miR-9 | ||||||
| miR-153 | ||||||
| miR-10a | Mouse | Brain | Wang | |||
| miR-10b | ||||||
| miR-9 | ||||||
| miR-145 | ||||||
| miR-153a | Regulation of transcription | Zebrafish | Embryo | Soares | ||
| miR-30d | ||||||
| miR-725 | ||||||
| let7k | ||||||
| miR-100 | ||||||
| miR-738 | ||||||
| miR-732 | ||||||
| Gold nanoparticles | let-7a | Cell proliferation | Mouse | Liver and lung | Balansky | |
| k-RAS activation | ||||||
| Apoptosis | ||||||
| miR-183 | Apoptosis | |||||
| Cell adhesion | ||||||
| Maternal smoking | miR-146a | Pro-survival | Human | Placenta | Maccani | |
| NF-κβ pathway | ||||||
| miR-16 | Cell cycle/cell proliferation transcription factors | |||||
| miR-21 | NF-κβ/TLR4 pathway | |||||
| miR-223 | Progenitor cell proliferation/granulocyte differentiation | Human | Cord blood | Herberth | ||
| PCBs | miR-762 | Cardiovascular differentiation | Mouse | P19 cells embryonal carcinoma | Zhu | |
| miR-29a | Cardiovascular differentiation | |||||
| miR-324- | Heart development | |||||
| 5p | ||||||
| PFOS | miR-19b-c | Brain and nervous system development | Zebrafish | Embryo | Zhang | |
| Apoptosis | ||||||
| miR-19d | ||||||
| miR-181b-c | ||||||
| miR-735 | ||||||
| miR-739 | ||||||
| miR-297 | Rat | Brain | Wang | |||
| miR-672 | ||||||
| TCDD | mir-122 | Metabolism | Mouse | Thymus | Singh | |
| miR-181a | T-cell sensitivity and selection | |||||
| miR-23a | Apoptosis | |||||
| miR-18b | Apoptosis | |||||
| miR-31 | Metabolism | |||||
| miR-182 | Metabolism | |||||
| Endogenous factor | ||||||
| Hypoxia | mR-520c-3p | Human | Placenta | Donker | ||
| Paternal stress | miR-322 | TGF superfamily | Mouse | Brain | Morgan | |
| miR-574-3p | ||||||
| miR-873 | ||||||
| Nutrition | ||||||
| High-fat diet | miR-483* | Mouse | Liver | Zhang | ||
AhR, aryl hydrocarbon receptor; BAX, BCL2-associated X protein; BCL2L2, BCL2-like 2; BPA, bisphenol A; CDK5, cyclin-dependent kinase 5; CYP1A1, cytochrome P450, family 1, subfamily A, polypeptide 1; EDA, ectodysplasin A; ELAVL2, ELAV-like neuron-specific RNA binding protein 2; Fas, Fas cell surface death receptor; FasL, Fas ligand; GSK3B, glycogen synthase kinase 3 beta; HOXa1, homeobox A1; Jag-1, jagged 1; k-RAS, Kirsten rat sarcoma viral oncogene homolog; NFkB, nuclear factor kappa B; NKX2.5, NK2 homeobox 5; PCBs, polychlorinated biphenyls; PFOS, perfluorooctane sulfonate; PLAG1, pleiomorphic adenoma gene 1; Pou4f1, POU class 4 homeobox 1; Pou5f1, POU class 5 homeobox 1; SATB1, SATB homeobox 1; Smad1, SMAD family member 1; Sox11b, SRY-box containing gene 11b; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TGF, transcription growth factor; TLR, Toll-like receptor; TLR4, Toll-like receptor 4; TRAF6, TNF receptor-associated factor 6; Vsx1, visual system homeobox 1; Wnt1, wingless-type MMTV integration site family, member 1; ZSWIM3, zinc finger, SWIM-type containing 3.